Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroblastoma 2Glioma 2Glioblastoma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Hepatoblastoma 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × irinotecan sucrosofate × CNS × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡